Home › Carotid Artery Disease › NCT02240862
The CREST-2 Registry
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria Asymptomatic patients: Age ≥ 18 and ≤ 80 and any one of the following 1. ≥70% stenosis, standard surgical risk for CEA 2. ≥70% stenosis, high anatomic risk for CEA 3. ≥70% stenosis, high physiologic risk for CEA Symptomatic patients: Symptomatic patients are defined by the following characteristics: Ipsilateral carotid Transient Ischemic Attack (TIA), with neurologic symptoms persisting less than 24 hours; Ipsilateral non-disabling stroke: Modified Rankin Scale (mRS) ≤ 3; and Ipsilateral transient monocular blindness: amaurosis fugax. \[Source: current Medicare NCD for CAS\] Age ≥ 18 and ≤ 80 and any one of the following 1. ≥50% stenosis, standard surgical risk for CEA 2. 50% to 69% stenosis, high anatomic risk for CEA 3. 50% to 69% stenosis, high physiologic risk 4. ≥70% stenosis, high anatomic and/or physiologic risk for CEA - currently covered by Medicare, but sites are strongly encouraged to voluntarily include these patients in C2R 5. ≥70% stenosis, post-CEA and -CAS - currently covered by Medicare, but sites are strongly encouraged to voluntarily include these patients in C2R 6. ≥70% stenosis, post-irradiation - currently covered by Medicare, but sites are strongly encouraged to voluntarily include these patients in C2R Exclusion Criteria: Patients with any one of the following conditions are ineligible for enrollment in C2R 1. NYHA Class IV CHF 2. COPD on chronic continuous oxygen therapy 3. Severe (Class Childs D) liver failure 4. End-stage renal failure requiring dialysis 5. Cancer with metastatic spread and/or undergoing active chemotherapeutic treatment 6. Any dementia considered greater than "mild"
About the study
The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists' eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease. Patients will be followed for the occurrence of post-procedural complications. The primary safety and quality endpoint will be the occurrence of any stroke or death within the 30-day period following the stenting procedure. The safety and quality results from C2R will guide selection of interventionists for participation in the CREST-2 randomized clinical trial. Enrollment into C2R will begin in 2015 and continue until publication of the primary results of the randomized trial.
What is being tested
- Carotid Artery Stent (device)
Sponsor: University of Maryland, Baltimore · Participants: 8,000 · Started: 2015-02
Contact the study team
- Kimberlly A Castro-Roberts, MBA, CCRC · Phone: 410-706-3941
Official record on ClinicalTrials.gov — NCT02240862
Locations in the U.S.
| Maryland | University of Maryland - Administrative Center, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.